Innovating pharmaceuticals for life


Philip Satow

Phillip Satow serves as chairman of Nutrition 21, Inc. He is the co-founder of Noven Therapeutics, LLC (formerly JDS Pharmaceuticals, LLC) and served as its chairman and chief executive officer. Prior to founding JDS, he served as executive vice president of Forest Laboratories Inc., one of the leading specialty pharmaceutical companies in the U.S., where he launched Forest’s first $1 billion product – the anti-depressant Celexa. Prior to joining Forest, he served as vice president and general manager of the Wallace Laboratories Division of Carter–Wallace. In addition, he has held a variety of executive positions at Pfizer, including director of marketing of Pfizer Laboratories and vice president of Pfizer Europe.

Satow is a founder and president of the board of The Jed Foundation and is a member of the Executive Committee of the National Action Alliance for Suicide Prevention. He also serves on the Board of Directors of Emmaus Life Sciences, Inc., Noven Pharmaceuticals, Inc. and Oldtech, Inc. Satow served for four years as a U.S. Naval Officer.